Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Amalgamated Bank

Amalgamated Bank lessened its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 2.2% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 28,803 shares of the specialty pharmaceutical company’s stock after selling 641 shares during the quarter. Amalgamated Bank’s holdings in Jazz Pharmaceuticals were worth $3,547,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in JAZZ. Pacer Advisors Inc. grew its position in shares of Jazz Pharmaceuticals by 15.3% in the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock valued at $233,892,000 after purchasing an additional 278,465 shares during the period. Cinctive Capital Management LP acquired a new stake in Jazz Pharmaceuticals in the 3rd quarter worth about $14,277,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Jazz Pharmaceuticals by 135.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock worth $19,394,000 after buying an additional 100,112 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in shares of Jazz Pharmaceuticals by 47.7% during the third quarter. Point72 Asset Management L.P. now owns 268,783 shares of the specialty pharmaceutical company’s stock valued at $29,945,000 after acquiring an additional 86,768 shares during the last quarter. Finally, Two Sigma Advisers LP lifted its position in shares of Jazz Pharmaceuticals by 393.0% in the third quarter. Two Sigma Advisers LP now owns 106,000 shares of the specialty pharmaceutical company’s stock valued at $11,809,000 after acquiring an additional 84,500 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Price Performance

NASDAQ:JAZZ opened at $143.53 on Friday. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $148.06. The stock’s fifty day moving average is $126.28 and its two-hundred day moving average is $118.79. The company has a market capitalization of $8.68 billion, a P/E ratio of 20.22, a P/E/G ratio of 1.04 and a beta of 0.56. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

Wall Street Analyst Weigh In

JAZZ has been the subject of several research reports. Robert W. Baird boosted their price target on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research report on Monday, November 18th. Cantor Fitzgerald lowered shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and upped their target price for the stock from $140.00 to $150.00 in a report on Wednesday. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. Barclays restated an “overweight” rating and set a $200.00 price target (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday. Finally, HC Wainwright reiterated a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Two investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $182.47.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the completion of the transaction, the chief executive officer now owns 425,525 shares of the company’s stock, valued at $52,522,550.75. This trade represents a 0.35 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In the last ninety days, insiders sold 5,053 shares of company stock valued at $617,442. 4.20% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.